Clinical trial NCT03915405: KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer
Official title: An Open-label, Phase 1 Study of KHK2455 in Combination With Avelumab in Adult Subjects With Locally Advanced or Metastatic Urothelial Carcinoma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Urothelial Carcinoma
Lead sponsor: Kyowa Kirin Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2019-04-16
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a two-part (dose-escalation, dose-expansion), multicenter, open-label Phase 1 study of KHK2455 in combination with avelumab in adult subjects with locally advanced or metastatic urothelial carcinoma (including bladder, urethra, ureters, and renal pelvis).

Detailed description: This is a two-part (dose-escalation, dose-expansion), multicenter, open-label Phase 1 study of KHK2455 in combination with avelumab in adult subjects with locally advanced or metastatic urothelial carcinoma (including bladder, urethra, ureters, and renal pelvis). Subjects will be screened for entry into this study after signing informed consent. Subjects must meet inclusion/exclusion criteria to participate in this study.

* Part 1 (dose-escalation phase) has a modified 3+3 design that will evaluate the safety and tolerability and identify the MTD or highest protocol-defined dose, in the absence of exceeding the MTD.
* Part 2 (cohort-expansion phase) will further explore the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity for the combination regimen at the MTD or highest dose level tested.

Eligibility criteria: Inclusion Criteria:

* Subjects may be male or female and must be ≥ 18 years of age; have an ECOG PS of 0 or 1; and a life expectancy of \> 3 months in the Investigator's judgment;
* Subjects are able to understand and willing to sign the ICF, according to institutional standards, prior to the initiation of any study related procedures
* Subjects must have histological or cytological evidence of metastatic or advanced urothelial carcinoma (including bladder, urethra, ureters, and renal pelvis that has predominantly transitional cell or urothelial features); and have measurable neoplastic disease according to RECIST v1.1 criteria
* Subjects must have been previously treated with a platinum-based therapy and progressed; OR Been previously treated with platinum based adjuvant or neo-adjuvant therapy and relapsed or progressed; OR
* Be platinum-based chemotherapy intolerant or ineligible; OR
* Have progressed during or after treatment with approved PD-1/PD-L1 inhibitors
* Subjects must have a tumor accessible for fresh biopsy at the baseline visit and for IDO assessment. If current circumstances prohibit the biopsy procedure (e.g., temporary hospital protocol restrictions, regulatory or local authority requirements, etc.) then archived tissue from previous biopsies (fresh frozen tissue \< 9 months and formalin fixed-paraffin embedded \[FFPE\] block of ≤ 24 months) without intervening checkpoint inhibitors can substitute for a fresh baseline biopsy;
* Subjects must be able to swallow the solid (encapsulated) dosage form of KHK2455

Exclusion Criteria:

* Subjects who have been previously treated with avelumab or any IDO1 inhibitor or CTLA-4, PD-1/PD-L1 checkpoint inhibitors; or any investigational immunotherapy including but not limited to anti-cancer vaccines or oncotropic viruses
* Subjects with prior or current liver metastases;
* Subjects with a history of organ transplant or allogeneic bone marrow transplant;
* Subjects with pre-existing uveitis or other known clinically meaningful retinal disorders as determined by a local ophthalmologist

Primary outcomes:
measure: Number of participants with treatment-related adverse events as assessed by CTCAE v.5.0
timeFrame: up to 24 months
Secondary outcomes:
Other outcomes:
Locations:
city: Saint Petersburg
country: United States
facility: Kyowa Research Site USA001
state: Florida
city: Iowa City
country: United States
facility: Kyowa Research Site USA005
state: Iowa
city: Santa Fe
country: United States
facility: Kyowa Research Site USA006
state: New Mexico
city: Houston
country: United States
facility: Kyowa Research Site USA 009
state: Texas
city: Milwaukee
country: United States
facility: Kyowa Research Site USA007
state: Wisconsin
city: Barcelona
country: Spain
facility: Kyowa Research Site ESP002
city: Barcelona
country: Spain
facility: Kyowa Research Site ESP003
city: Madrid
country: Spain
facility: Kyowa Research Site ESP004
city: Madrid
country: Spain
facility: Kyowa Research Site ESP001
Study officials:
References: